Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin)

Clinical and Experimental Optometry

Volumn 92, Issue 1, 2009, Pages 34-37

  Thew, Michael ^a,b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b CAIRNS BASE HOSPITAL   (Australia)

Author keywords

Bevacizumab; Proliferative diabetic retinopathy; Retinal neovascularisation

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DIABETIC RETINOPATHY; FEMALE; HOSPITALIZATION; HUMAN; INJECTION; LASER COAGULATION; MULTIMODALITY CANCER THERAPY; RETINA NEOVASCULARIZATION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; LIGHT COAGULATION; RETINAL NEOVASCULARIZATION; SEVERITY OF ILLNESS INDEX; VITREOUS BODY; YOUNG ADULT;

EID: 58149159388     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2008.00295.x     Document Type: Article

References (27)

1. nd ed. Malden, Mass : Blackwell Publishers, 2005.
2. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocrinol Rev 2004 25 : 581 611.
3. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005 : 25 : 111 118.
4. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogenesis 1999 : 3 : 9 14.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 329 : 977 986
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 837 853
7. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 317 : 703 713
8. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002 61 : 1086 1097.
9. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978 85 : 82 106.
10. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS Report Number 8. Ophthalmology 1981 88 : 583 600.
11. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. Ophthalmology 1991 98 suppl : 741 756.
12. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening and novel therapies. Diabetes Care 2003 26 : 2653 2664.
13. Pahor D. Visual field loss after argon laser pan-retinal photocoagulation in diabetic retinopathy: full-versus mild-scatter coagulation. Int Ophthalmol 1998 22 : 313 319.
14. Buckley SA, Jenkins L, Benjamin L. Fields, DVLC and panretinal photocoagulation. Eye 1992 6 : 623 625
15. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003 136 : 122 135.
16. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004 15 : 508 518.
17. Bhisitkul, RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006 90 : 1542 1547.
18. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997 57 : 4593 4599.
19. Hurwitz HI, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth JD, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 350 : 2335 2342.
20. Yang JC, Harworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, and anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 349 : 427 434.
21. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005 36 : 331 335.
22. Avery RL, Pieramici D, Rabena M, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006 : 113 : 363 372.
23. Friedlander SM, Welch RM. Vanishing disc neovascularisation following intravitreal bevacizumab (Avastin) injection. Arch Ophthalmol 2006 124 : 1365.
24. Avery RL. Regression of retinal and iris neovascularisation after intravitreal bevacizumab (Avastin) treatment. Retina 2006 26 : 352 354.
25. Mason JO 3rd., Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006 142 : 685 688.
26. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006 34 : 802 803.
27. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ, for the Pan-American Collaborative Retina Study Group PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008 246 : 81 87.